Skip to main content

Advertisement

Table 2 The summarize of treatment doses and toxicities for the 14 patients received crizotinib treatment after acquired resistance to first generation EGFR-TKI

From: Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Patient no. Age/gender EGFR mutataion Treatment after acquired resistance Grade 3–4 toxicities Reduce dose
1 55/male 21L858R Icotinib 125 mg/tid + crizotinib 250 mg/bid No No
2 65/female 21L858R Gefitinib 250 mg/qd + crizotinib 250 mg/bid Aminotransferase rise Gefitinib 250 mg/qd + crizotinib 200 mg/bid
3 53/male 21L858R Icotinib 125 mg/tid + crizotinib 250 mg/bid No No
4 49/male 21L858R Gefitinib 250 mg/qd + crizotinib 250 mg/bid No No
5 62/female 21L858R Elotinib 150 mg/qd + crizotinib 250 mg/bid Aminotransferase rise Elotinib 150 mg/qd + crizotinib 200 mg/bid
6 60/female 19 exon deletion Icotinib 125 mg/tid + crizotinib 250 mg/bid No No
7 37/male 19 exon deletion Crizotinib 250 mg/bid No No
8 64/male 21L858R Crizotinib 250 mg/bid No No
9 71/female 21L858R Crizotinib 250 mg/bid Nausea Crizotinib 200 mg/bid
10 64/female 21L858R Crizotinib 250 mg/bid No No
11 58/male 21L858R Crizotinib 250 mg/bid No No
12 41/female 21L858R Crizotinib 250 mg/bid No No
13 58/female 21L858R Crizotinib 250 mg/bid No No
14 53/female 21L858R Crizotinib 250 mg/bid No No